Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data-MedSci.cn

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

Haller, MJ; Long, SA; Blanchfield, JL; Schatz, DA; Skyler, JS; Krischer, JP; Bundy, BN; Geyer, SM; Warnock, MV; Miller, JL; Atkinson, MA; Becker, DJ; Baidal, DA; DiMeglio, LA; Gitelman, SE; Goland, R; Gottlieb, PA; Herold, KC; Marks, JB; Moran, A; Ro

Haller, MJ (reprint author), Univ Florida, Inst Diabet, Gainesville, FL 32610 USA.

DIABETES, 2019; 68 (6): 1267

Abstract

A three-arm, randomized, double-masked, placebo-controlled phase 2b trial performed by the Type 1 Diabetes TrialNet Study Group previously demonstrate......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA(1c), and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data

科室

工具

服务